amsacrine has been researched along with Down Syndrome in 3 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease." | 2.72 | Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. ( de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K, 2006) |
| "The prognosis for DS acute myeloid leukemia (AML) is better than for non-DS AML, but the clinical outcome of DS acute lymphoblastic leukemia (ALL) is equal to that of non-DS ALL." | 1.31 | Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. ( Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rao, A | 1 |
| Hills, RK | 1 |
| Stiller, C | 1 |
| Gibson, BE | 1 |
| de Graaf, SS | 1 |
| Hann, IM | 1 |
| O'Marcaigh, A | 1 |
| Wheatley, K | 1 |
| Webb, DK | 1 |
| Zwaan, CM | 1 |
| Kaspers, GJ | 1 |
| Pieters, R | 1 |
| Hählen, K | 1 |
| Janka-Schaub, GE | 1 |
| van Zantwijk, CH | 1 |
| Huismans, DR | 1 |
| de Vries, E | 1 |
| Rots, MG | 1 |
| Peters, GJ | 1 |
| Jansen, G | 1 |
| Creutzig, U | 1 |
| Veerman, AJ | 1 |
| Simon, JH | 1 |
| Tebbi, CK | 1 |
| Freeman, AI | 1 |
| Brecher, ML | 1 |
| Green, DM | 1 |
| Sandberg, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ACUTE MYELOID LEUKAEMIA TRIAL 12[NCT00002658] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1994-01-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amsacrine and Down Syndrome
| Article | Year |
|---|---|
Acute megakaryoblastic leukemia associated with mosaic Down's syndrome.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 17; Clone Cells; | 1987 |
1 trial available for amsacrine and Down Syndrome
| Article | Year |
|---|---|
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyta | 2006 |
1 other study available for amsacrine and Down Syndrome
| Article | Year |
|---|---|
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool; | 2002 |